ACTG A5201 ATAZANAVIR/RITONAVIR AFTER SUSTAINED VIROLOGIC SUPPRESSION

ACTG A5201 持续病毒学抑制后的阿扎那韦/利托那韦

• 批准号: 7604851
• 负责人: JEFFERY L MEIER
• 金额: $ 0.08万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604851
• 关键词: Aftercare; Atazanavir; Clinical; Combined Modality Therapy; Computer Retrieval of Information on Scientific Projects Database; Failure; Funding; Future; Genotype; Grant; Guidelines; HIV-1; Institution; Maintenance Therapy; Measurement; Plasma; Purpose; RNA; Research; Research Personnel; Resources; Risk; Ritonavir; Source; Time; United States National Institutes of Health; Viral Load result; Week; antiretroviral therapy; day

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary purpose of this study is to evaluate the risk of virologic failure in subjects 24 weeks after treatment with ritonavir-boosted atazanavir (ATV/RTV) maintenance therapy alone. Virologic failure is defined as 2 consecutive plasma HIV-1 RNA measurements >200 copies/mL. Subjects with HIV-1 RNA measurements >200 copies mL must return within 30 days for confirmation of virologic failure, at which point real-time genotyping will be performed if the second viral load is >1000 copies/mL. Decisions about future antiretroviral therapy will be made according to current clinical guidelines and may include resumption of previous combination therapy. All subjects who permanently discontinue study treatment on Step 2, including those who change therapy due to virologic failure, will be followed off treatment on study.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此，可以在其他清晰的条目中表示。列出的机构是 对于中心，这不一定是调查员的机构。 这项研究的主要目的是仅利用利托那韦促进的阿扎纳维尔（ATV/RTV）维持治疗治疗后24周评估受试者的病毒衰竭风险。 病毒衰竭定义为连续2个血浆HIV-1 RNA测量> 200份/ml。 HIV-1 RNA测量的受试者> 200份ML必须在30天内返回以确认病毒性衰竭，此时，如果第二个病毒负荷为> 1000拷贝/mL，则将进行实时基因分型。 关于未来抗逆转录病毒疗法的决定将根据当前的临床指南做出，可能包括恢复以前的联合疗法。 在第2步中永久停止研究治疗的所有受试者，包括那些因病毒衰竭而改变治疗的受试者，都将在研究中进行治疗。